Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment
Bill Of Health
SEPTEMBER 28, 2023
Such a provision could prevent the public from paying twice for publicly-funded medical products—first through their taxes subsidizing government funded research and development, and second to procure the product in an inflated U.S. Moreover, the NASDAQ Biotechnology Index increased by 374% from 1995 to 2000. In 1989, the U.S.
82 
Let's personalize your content